BARDA gives notice to Advanced Life Sciences for Restanza funding proposal

The Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services has given notice to Advanced Life Sciences that an initial technical evaluation of the company's funding proposal for Restanza has been completed.

The $15 million funding proposal for Restanza as a biodefense countermeasure was identified by BARDA as a scientifically and technically sound proposal that is important to program goal and objectives. BARDA also identified that the proposal may require further development and may be recommended for acceptance subject to funds availability.

Advanced Life Sciences was invited to submit additional information to BARDA to allow it to make a final determination on the appropriateness of the proposal to enter into contract negotiations.

"The goal of our biodefense program is to attract development funding from the U.S. Government that will ultimately lead to the acquisition of Restanza for the Strategic National Stockpile," Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life sciences, said. "The notice that we received from BARDA gives us confidence that we can attract additional development funding in the near term and the clearly defined regulatory pathway for the biodefense indications established with FDA will significantly increase our prospects for further development and acquisition contracts with the Department of Health and Human Services and the Department of Defense."